3.81
-0.085(-2.19%)
Currency In USD
| Previous Close | 3.89 |
| Open | 3.8 |
| Day High | 4.03 |
| Day Low | 3.76 |
| 52-Week High | 5.63 |
| 52-Week Low | 1.64 |
| Volume | 8.79M |
| Average Volume | 15.38M |
| Market Cap | 1.28B |
| PE | -3.55 |
| EPS | -1.09 |
| Moving Average 50 Days | 3.12 |
| Moving Average 200 Days | 2.5 |
| Change | -0.02 |
Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas
GlobeNewswire Inc.
Feb 24, 2026 12:00 PM GMT
50% Objective Response Rate (ORR) in Advanced Sarcomas Significant Market Opportunity with More than 8,000 Patients Diagnosed Annually in the U.S. and Europe SAN CARLOS, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDA
Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026
GlobeNewswire Inc.
Feb 11, 2026 9:05 PM GMT
SAN CARLOS, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patient
Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma
GlobeNewswire Inc.
Feb 05, 2026 10:15 PM GMT
52% Amtagvi Response Rate with Two or Fewer Prior Lines of Therapy 73% Overall Disease Control RateSAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on inn